|
| Category | FY | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA200854-03
|
|
Characterizing Molecular Subtypes of Ovarian Cancer in African-American Women
|
DOHERTY, JENNIFER
|
UNIVERSITY OF UTAH
|
UT
|
$557,804
|
|
Ovarian Cancer
|
2018
|
NIAID
|
5R01AI109008-06
|
|
Origin of the innate immunity suppression caused by nairovirus' protease activity
|
PEGAN, SCOTT
|
UNIVERSITY OF GEORGIA
|
GA
|
$311,305
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA043054-31
|
|
Nuclear Function of Abl in DNA Damage Response
|
WANG, JEAN
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
CA
|
$387,500
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA202919-03
|
|
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer
|
ZHANG, RUGANG
|
WISTAR INSTITUTE
|
PA
|
$434,625
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA194498-03
|
|
CDK12 in Ovarian Cancer
|
KARNITZ, LARRY
|
MAYO CLINIC ROCHESTER
|
MN
|
$393,922
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA194064-04
|
|
Combination Therapy of OvCA with Oligonucleotides and Photodynamic Therapy
|
MING, XIN
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$283,650
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA136494-10
|
|
Molecular Mechanism of Antiangiogenic Properties of Gold Nanoparticle
|
MUKHERJEE, PRIYABRATA
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$304,695
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA202846-03
|
|
Targeted therapy of peritoneal carcinomatosis using theranostic nanoparticles
|
YANG, LILY
|
EMORY UNIVERSITY
|
GA
|
$411,268
|
|
Ovarian Cancer
|
2018
|
NIMHD
|
5R01MD009697-03
|
|
Spatiotemporal Analysis of Disparities in Ovarian Cancer Treatment and Survival
|
BRISTOW, ROBERT
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
CA
|
$386,250
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA196631-03
|
|
A network platform to connect drug response and prognosis phenotypes for cancers
|
LI, HU
|
MAYO CLINIC ROCHESTER
|
MN
|
$395,911
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA203348-03
|
|
Blocking NK cell shedding of CD16a to increase cancer cell killing
|
WALCHECK, BRUCE
|
UNIVERSITY OF MINNESOTA
|
MN
|
$447,909
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA211016-02
|
|
Immune Impact on Cancer Chemoresistance
|
ZOU, WEIPING
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$611,871
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA186700-04
|
|
Study of biomarkers in ovarian cancer: modulation by activity & diet intervention
|
THOMSON, CYNTHIA
|
UNIVERSITY OF ARIZONA
|
AZ
|
$687,633
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA136512-08
|
|
BRCA1 Function in Post-Damage Nuclear Foci
|
LIVINGSTON, DAVID
|
DANA-FARBER CANCER INST
|
MA
|
$515,452
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA184088-04
|
|
Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy
|
KABANOV, ALEXANDER
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$344,549
|
|
Ovarian Cancer
|
2018
|
NIBIB
|
5R01EB019458-04
|
|
Pre-clinical quantitation of ovarian cancer tumor burden using Magnetic Particle Imaging and non-dilutive cell labeling
|
CONOLLY, STEVEN
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$462,841
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA119171-11
|
|
Nutrition and Physical Activity Assessment Study (NPAAS)
|
NEUHOUSER, MARIAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$791,418
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA172743-06
|
|
Impact of BRCA Testing on Newly Diagnosed U.S. Breast Cancer Patients
|
SUTPHEN, REBECCA
|
UNIVERSITY OF SOUTH FLORIDA
|
FL
|
$122,930
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA190498-04
|
|
gp130 as a novel therapeutic target in ovarian cancer
|
NEAMATI, NOURI
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$376,320
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA211175-02
|
|
Averting recurrent and resistant ovarian tumors
|
WANG, QIEN
|
OHIO STATE UNIVERSITY
|
OH
|
$451,109
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA211625-02
|
|
Comparative Effectiveness of Interventions to Increase Guideline-based Genetic Counseling in Ethnically and Geographically Diverse Cancer Survivors
|
KINNEY, ANITA
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
NM
|
$608,440
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA193249-03
|
|
Behavioral Influences on Ovarian Cancer Progression: Role of Chemoresistance
|
LUTGENDORF, SUSAN
|
UNIVERSITY OF IOWA
|
IA
|
$603,615
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R00CA194318-04
|
|
Targeting Wnt signaling to overcome PARP inhibitor resistance in ovarian cancer
|
BITLER, BENJAMIN
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$249,001
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA211707-02
|
|
Functional Effects of Ovarian Cancer Risk Variants
|
GAYTHER, SIMON
|
CEDARS-SINAI MEDICAL CENTER
|
CA
|
$622,079
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P30CA015704-43
|
5446
|
Research Program: Women's Cancer
|
PORTER, PEGGY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$69,359
|
|
Ovarian Cancer
|
2018
|
NIGMS
|
5R01GM113940-05
|
|
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers
|
YOU, YOUNGJAE
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$303,400
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA190423-04
|
|
Mechanisms of PARP Inhibitor Resistance in Ovarian Cancer
|
KAUFMANN, SCOTT
|
MAYO CLINIC ROCHESTER
|
MN
|
$372,824
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA182832-05
|
|
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer
|
MATEI, DANIELA
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$323,695
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R00CA179137-05
|
|
Understanding the origin,initiation,and progression of high-grade serous ovarian cancer
|
KIM, JAEYEON
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$236,746
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R00CA194309-04
|
|
Nucleotide Metabolism in Senescence and Platinum Resistance of Ovarian Cancer
|
AIRD, KATHERINE
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$210,465
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R01CA211574-01A1
|
|
Genomic and Transcriptomic Analysis of Breast and Ovarian Cancers
|
SCHILDKRAUT, JOELLEN
|
UNIVERSITY OF VIRGINIA
|
VA
|
$703,749
|
|
Ovarian Cancer
|
2018
|
NIBIB
|
5F32EB023101-02
|
|
Sequence- and Stereocontrolled Triazolium-containing Precise Polymers for siRNA Complexation and Delivery
|
GOLDER, MATTHEW
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$59,038
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P30CA044579-27
|
5844
|
Women's Oncology Program - WON
|
SHUPNIK, MARGARET
|
UNIVERSITY OF VIRGINIA
|
VA
|
$55,469
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R01CA222251-01
|
|
Identification of USP13 as a therapeutic target for ovarian cancer
|
LU, XIONGBIN
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$379,129
|
|
Ovarian Cancer
|
2018
|
NCI
|
5F30CA213737-02
|
|
A Systems Biology Approach to Mechanisms of PARP Inhibitor Resistance in Ovarian Cancer
|
MCGEHEE, CORDELIA
|
MAYO CLINIC ROCHESTER
|
MN
|
$44,724
|
|
Ovarian Cancer
|
2018
|
NCI
|
1K08CA222385-01
|
|
The role of fallopian tube microbiome in ovarian carcinogenesis
|
YU, BO
|
UNIVERSITY OF WASHINGTON
|
WA
|
$167,724
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R00CA175292-05
|
|
Targeting Determinants of OvCa Metastases in Engineered 3D Microfluidic Platforms
|
RIZVI, IMRAN
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$238,772
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA197780-03
|
|
Examining the role of the miR-181a:Wnt/B-catenin axis in ovarian cancer
|
DIFEO, ANALISA
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$363,581
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA200231-04
|
|
PHARMACOLOGICAL MODULATION OF POLY(ADP-RIBOSE) METABOLISM
|
TAINER, JOHN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$345,984
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R21CA216652-01A1
|
|
Genetically Modified Natural Killer Cells for Cancer Immunotherapy
|
MORIARITY, BRANDEN
|
UNIVERSITY OF MINNESOTA
|
MN
|
$167,476
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R15CA213103-01A1
|
|
Improving tumor specificity and overcoming drug resistance of proteasome inhibitors by a dual-targeted drug delivery system
|
ZHU, LIN
|
TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
|
TX
|
$443,794
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA204119-03
|
|
Early Detection of Ovarian Cancer Through Epigenetic Factors in the WHI
|
GENKINGER, JEANINE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$415,462
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R21CA216796-01A1
|
|
Clinical Evaluation of an Implantable Lab-in-a-patient microdevice that measures in-situ response to therapies in advanced ovarian cancer
|
JONAS, OLIVER
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$183,736
|
|
Ovarian Cancer
|
2018
|
NCI
|
5F30CA206398-03
|
|
Novel PD-L1 signals regulating anti-tumor immunity and immunotherapy responses
|
CLARK, CURTIS
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
TX
|
$40,028
|
|
Ovarian Cancer
|
2018
|
NCI
|
2R01CA109545-10A1
|
|
Receptor Cross-Talk in Early Metastatic Dissemination
|
STACK, MARY
|
UNIVERSITY OF NOTRE DAME
|
IN
|
$330,244
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U10CA180860-05
|
|
Integrated Translational Genoproteomics Center at Washington University
|
MUTCH, DAVID
|
WASHINGTON UNIVERSITY
|
MO
|
$451,509
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R03CA223623-01
|
|
The role of CREB3L1 in synergy between oncolytic vaccinia virus and doxorubicin
|
KOZBOR, DANUTA
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$85,900
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R35CA197605-03
|
|
Mucins and immune cell interactions in ovarian cancer pathogenesis & progression
|
CRAMER, DANIEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$966,086
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA211648-02
|
|
Identifying the Drivers and Targeting Chemo Resistance in Ovarian Cancer
|
ADLI, MAZHAR
|
UNIVERSITY OF VIRGINIA
|
VA
|
$432,788
|
|
Ovarian Cancer
|
2018
|
NCCIH
|
5R01AT008824-03
|
|
Botanical derived progestins and their impact on women's health
|
BURDETTE, JOANNA
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$359,775
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA181543-05
|
|
Analysis of Intratumoral Crosstalk in Clonal Populations of OvarianTumor Cells
|
BRUGGE, JOAN
|
HARVARD MEDICAL SCHOOL
|
MA
|
$394,740
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R33CA214310-01A1
|
|
Live Tumor Culture Core and Tissue Specific Culture (TSC) System for Human Cancers
|
INCE, TAN
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$382,215
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R01CA214606-01A1
|
|
Vitamin D and Progestins for the Chemoprevention of Fallopian Tube/Ovarian Cancer
|
RODRIGUEZ, GUSTAVO
|
NORTHSHORE UNIVERSITY HEALTHSYSTEM
|
IL
|
$370,707
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA190176-04
|
|
Effector T Cell Trafficking in Ovarian Cancer
|
ZOU, WEIPING
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$513,972
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA207407-02
|
|
Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers
|
STEPHAN, MATTHIAS
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$371,925
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA207260-02
|
|
Exploring factors related to racial disparities in ovarian cancer incidence and survival: the OCWAA consortium
|
SCHILDKRAUT, JOELLEN
|
UNIVERSITY OF VIRGINIA
|
VA
|
$605,285
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA215483-02
|
|
Experimental Therapeutics by targeting Spleen Tyrosine Kinase
|
SHIH, IE-MING
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$374,971
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA200507-02
|
|
Optimizing Delivery of Oncolytic Measles Virus Strains with Cell Carriers
|
GALANIS, EVANTHIA
|
MAYO CLINIC ROCHESTER
|
MN
|
$592,664
|
|
Ovarian Cancer
|
2018
|
NIGMS
|
1R01GM123018-01A1
|
|
Mechanisms of heterochromatin replication
|
SMOLKA, MARCUS
|
CORNELL UNIVERSITY
|
NY
|
$301,056
|
|
Ovarian Cancer
|
2018
|
NIBIB
|
5R21EB024101-02
|
|
Microfluidic Integrative Circulating miRNA Profiling for Cancer Diagnosis
|
ZENG, YONG
|
UNIVERSITY OF KANSAS LAWRENCE
|
KS
|
$179,959
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R01CA214911-01A1
|
|
Ovarian Cancer Epigenetics, Immunity and Therapy
|
ZOU, WEIPING
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$621,601
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R37CA215436-01A1
|
|
A novel more effective genotoxic therapy for ovarian cancer
|
SIMPKINS, FIONA
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$368,288
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U01CA152637-08
|
|
Breast, Colorectal, and Ovary Cancer Clinical Validation Center
|
LI, CHRISTOPHER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$1,085,901
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA142698-09
|
|
Molecular mechanism and relevance of microRNAs in DSB repair pathway choice
|
CHOWDHURY, DIPANJAN
|
DANA-FARBER CANCER INST
|
MA
|
$409,002
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA175318-04
|
|
A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian Cancer
|
HATEFI, ARASH
|
RUTGERS, THE STATE UNIV OF N.J.
|
NJ
|
$354,563
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA197784-03
|
|
Comparison of 3 Modes of Genetic Counseling in High-Risk Public Hospital Patients
|
PASICK, RENA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$740,001
|
|
Ovarian Cancer
|
2018
|
NCI
|
2U01CA176726-06
|
|
Life Course Cancer Epidemiology Cohort in Women
|
WILLETT, WALTER
|
HARVARD SCHOOL OF PUBLIC HEALTH
|
MA
|
$2,423,825
|
|
Ovarian Cancer
|
2018
|
NCI
|
5K22CA193860-03
|
|
PCOS, Type II diabetes and ovarian cancer risk
|
HARRIS, HOLLY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$184,615
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA138835-09
|
|
The RAP80-BRCC36 Deubiquitinating Complex in DNA Repair
|
GREENBERG, ROGER
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$317,509
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA214043-02
|
|
Macrophage-based ovarian cancer immunotherapy
|
YULL, FIONA
|
VANDERBILT UNIVERSITY
|
TN
|
$358,683
|
|
Ovarian Cancer
|
2018
|
NCI
|
1K08CA215312-01A1
|
|
A genotype-phenotype study of tumors from patients with inherited mutations in DNA repair genes
|
MAXWELL, KARA
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$173,969
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA095175-14
|
|
Analysis of BRCA1 Recombination Functions
|
SCULLY, RALPH
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$328,700
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA203971-03
|
|
Deubiquitinases in regulation of BRCA1 pathway
|
YUAN, JIAN
|
MAYO CLINIC ROCHESTER
|
MN
|
$363,713
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA208244-02
|
|
Investigating 53BP1 'dephosphorylation' as a critical determinant of PARP
|
CHOWDHURY, DIPANJAN
|
DANA-FARBER CANCER INST
|
MA
|
$385,413
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R03CA208573-02
|
|
Metformin Supplementation for Ovarian Cancer Prevention: A Prospective Preclinical Study
|
RAMACHANDRAN, RAMESH
|
PENNSYLVANIA STATE UNIVERSITY-UNIV PARK
|
PA
|
$78,600
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R21CA204036-02
|
|
In vivo anti-PD1 gene therapy
|
LIEBER, ANDRE
|
UNIVERSITY OF WASHINGTON
|
WA
|
$168,970
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA214567-02
|
|
Isozyme-selective ALDH Inhibitors for Sensitizing Ovarian Cancer Stem-like Cells to Chemotherapy
|
LARSEN, SCOTT
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$603,477
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA183040-05
|
|
Ovarian cancer gene therapy using HPV pseudovirion
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$336,150
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA214545-02
|
|
Targeting Kinesin Family Member 15 for the Treatment of Cancer
|
GODWIN, ANDREW
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
KS
|
$623,043
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA215797-02
|
|
Obesity Increases Breast Cancer Penetrance in BRCA Mutation Carriers: A Role for Local and Systemic Factors
|
DANNENBERG, ANDREW
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
NY
|
$555,691
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U01CA200462-03
|
|
MD Anderson Cancer Center EDRN- CVC for Early Detection of Ovarian Cancer
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$910,580
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U01CA152990-08
|
|
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery
|
SKATES, STEVEN
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$1,323,251
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U01CA200469-03
|
|
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer
|
ZHANG, ZHEN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$441,524
|
|
Ovarian Cancer
|
2018
|
NHLBI
|
5R01HL132251-02
|
|
The Roles and Regulation of BRCA1 in Hematopoiesis
|
ROSS, THEODORA
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$405,000
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R43CA224602-01A1
|
|
Reversing/Blocking T cell suppression by extracellular vesicles as cancer therapy
|
BHATTA, MAULASRI
|
IMMUNE MODULATORY THERAPIES, LLC
|
NY
|
$280,928
|
|
Ovarian Cancer
|
2018
|
NICHD
|
5R01HD083930-03
|
|
Cryopreservation and Transplantation of Ovarian Cortical Tissue for Fertility Preservation
|
ZELINSKI, MARY
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
OR
|
$588,107
|
|
Ovarian Cancer
|
2018
|
NCI
|
1F30CA224986-01
|
|
Role of PAX8 in High Grade Serous Ovarian Cancer
|
RODGERS, LAURA
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$49,524
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA216234-02
|
|
Role of microbiota in therapy to ovarian cancer
|
RANDALL, TROY
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$426,139
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R01CA218664-01A1
|
|
Deep Ovarian Cancer Metabolomics
|
FERNANDEZ, FACUNDO
|
GEORGIA INSTITUTE OF TECHNOLOGY
|
GA
|
$410,432
|
|
Ovarian Cancer
|
2018
|
NCI
|
5F30CA217079-02
|
|
FemKube, the human female reproductive tract-on-a-chip, as a platform for studying high grade serous ovarian cancer and developing novel cancer chemotherapeutics
|
YOUNG, ALEXANDRIA
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$44,524
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA211932-02
|
|
Molecularly-Targeted Ultrasound in Ovarian Cancer
|
LUTZ, AMELIE
|
STANFORD UNIVERSITY
|
CA
|
$484,088
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA209818-02
|
|
Tumor-targeted nanoparticle-based delivery system for imaging and treatment of cancer
|
MINKO, TAMARA
|
RUTGERS, THE STATE UNIV OF N.J.
|
NJ
|
$463,244
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA215587-02
|
|
Multi-Modal Imaging of Psychostimulant Effects on Executive Function Post-RRSO
|
EPPERSON, C. NEILL
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$541,065
|
|
Ovarian Cancer
|
2018
|
NIGMS
|
5R35GM118175-03
|
|
Homologous recombination mechanisms in mammalian cells
|
JASIN, MARIA
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$531,434
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U01CA213759-02
|
|
Targeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modeling
|
LOPEZ-BERESTEIN, GABRIEL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$500,198
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA132755-11
|
|
Molecular Mechanisms of BRCA1-Dependent DNA Damage Response and Tumorogenesis
|
YU, XIAOCHUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$382,500
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA115483-14
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
CA
|
$345,281
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA196619-03
|
|
Credentialing Ovarian Cancer Models in the Context of the Dualistic Pathway Paradigm
|
CHO, KATHLEEN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$489,122
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA197976-04
|
|
The Hippo/Yap Signaling Pathway In Ovarian High Grade Serous Carcinoma
|
WANG, CHENG
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$376,067
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA182413-04
|
|
Origins of Ovarian Carcinoma
|
NIKITIN, ALEXANDER
|
CORNELL UNIVERSITY
|
NY
|
$421,580
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA206561-03
|
|
Quantitative assessment of the role of collagen alterations in ovarian cancer
|
CAMPAGNOLA, PAUL
|
UNIVERSITY OF WISCONSIN-MADISON
|
WI
|
$389,549
|
|
Ovarian Cancer
|
2018
|
NIGMS
|
5R35GM118026-03
|
|
Mechanisms of Genome Integrity
|
GREENE, ERIC
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$530,719
|
|
Ovarian Cancer
|
2018
|
NIGMS
|
5P20GM103625-07
|
5373
|
Dysbiosis-induced impairment of tumoral leukocyte extravasation
|
DINGS, RUUD
|
UNIV OF ARKANSAS FOR MED SCIS
|
AR
|
$283,100
|
|
Ovarian Cancer
|
2018
|
NCI
|
5K22CA207602-02
|
|
The role of short-form Ron (sfRon) kinase in the pathogenesis of high-grade serous ovarian cancer
|
BIENIASZ, MAGDALENA
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$159,705
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA176166-05
|
|
Identifying Biomarkers of Cisplatin Resistance Mechanisms in Ovarian Cancer
|
CANTOR, SHARON
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$347,563
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA188900-04
|
|
Novel immunological biomarkers ovarian cancer prognosis
|
SEGAL, BRAHM
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$632,858
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA193965-03
|
|
Redefining Normal: personalized CA125 cutpoints for ovarian cancer screening
|
TERRY, KATHRYN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$371,704
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R21CA191243-03
|
|
Label-free microfluidic enrichment of cancer cells from noncancer cells in ascites fluid
|
SULCHEK, TODD
|
GEORGIA INSTITUTE OF TECHNOLOGY
|
GA
|
$109,753
|
|
Ovarian Cancer
|
2018
|
NCI
|
5K07CA201013-03
|
|
Health Services Career Development: Improving Medical Decisions in Ovarian Cancer
|
MEYER, LARISSA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$170,626
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA204019-03
|
|
Multiplexed analysis of exosomes in cancer nano therapy
|
WEISSLEDER, RALPH
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$389,031
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA176078-05
|
|
Dissecting the role of STAT3 and targeting ovarian cancer
|
KARUPPAIYAH, SELVENDIRAN
|
OHIO STATE UNIVERSITY
|
OH
|
$320,524
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA195670-04
|
|
The Tumor Suppressor Role of SMARCA4 in SCCOHT
|
WEISSMAN, BERNARD
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$714,783
|
|
Ovarian Cancer
|
2018
|
NCI
|
2P30CA046592-29
|
7945
|
Cancer Epidemiology & Prevention (CEP) Program
|
PEARCE, CELESTE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$40,120
|
|
Ovarian Cancer
|
2018
|
NIBIB
|
5R01EB022033-03
|
|
Engineering an immuno-isolating hydrogel for restoring ovarian endocrine function
|
SHIKANOV, ARIELLA
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$374,475
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R01CA225680-01
|
|
Role of CPT1A as a lysine succinyltransferase in tumorigenesis
|
HITOSUGI, TARO
|
MAYO CLINIC ROCHESTER
|
MN
|
$363,713
|
|
Ovarian Cancer
|
2018
|
NIGMS
|
2SC1GM127278-05A1
|
|
Biodegradable nanocarriers and antibodies as targeting delivery vehicles for cancer metallodrugs
|
CONTEL, MARIA
|
BROOKLYN COLLEGE
|
NY
|
$392,500
|
|
Ovarian Cancer
|
2018
|
NIGMS
|
5R01GM097272-07
|
|
Cellular responses to DNA replication stress
|
SMOLKA, MARCUS
|
CORNELL UNIVERSITY
|
NY
|
$333,931
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U01CA214114-02
|
|
Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit
|
PAULOVICH, AMANDA
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$1,441,604
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R01CA225662-01
|
|
The contribution of RAD51C and RAD51D to breast and ovarian cancer
|
COUCH, FERGUS
|
MAYO CLINIC ROCHESTER
|
MN
|
$511,059
|
|
Ovarian Cancer
|
2018
|
NIGMS
|
5R35GM119512-03
|
|
Connecting BRCA1 functions with DNA crosslink sensitivity
|
LONG, DAVID
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
SC
|
$373,750
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R01CA225697-01
|
|
Genetic testing, treatment use, and mortality after diagnosis of breast and ovarian cancer: The Georgia-California GeneLINK Initiative
|
KURIAN, ALLISON
|
STANFORD UNIVERSITY
|
CA
|
$480,620
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA193578-04
|
|
Tunable Microchip Sorting of BRCA1 Nuclear Assemblies
|
KELLY, DEBORAH
|
VIRGINIA POLYTECHNIC INST AND ST UNIV
|
VA
|
$363,836
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R01CA227622-01
|
|
Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer
|
NAGRATH, DEEPAK
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$485,829
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R01CA227433-01
|
|
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE
|
GRINSTAFF, MARK
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
MA
|
$608,862
|
|
Ovarian Cancer
|
2018
|
NCI
|
1U01CA226055-01
|
|
Glycomics Laboratory for the Development of Ovarian Cancer Biomarkers
|
ABBOTT, KAREN
|
UNIV OF ARKANSAS FOR MED SCIS
|
AR
|
$768,101
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA211916-02
|
|
Nicotinamide N-Methyltransferase (NNMT) as a master regulator of cancer stroma
|
LENGYEL, ERNST
|
UNIVERSITY OF CHICAGO
|
IL
|
$371,806
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA207768-02
|
|
Role of MAST1 kinase in cisplatin resistant cancers
|
KANG, SUMIN
|
EMORY UNIVERSITY
|
GA
|
$356,850
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R21CA220078-02
|
|
The Role of Splice Quantitative Traits in Ovarian Cancer Pathogenesis
|
LAWRENSON, KATE
|
CEDARS-SINAI MEDICAL CENTER
|
CA
|
$181,178
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R21CA226302-01
|
|
Targeting the IL-6 - SPINK1 regulatory axis in ovarian clear cell carcinoma
|
RADISKY, EVETTE
|
MAYO CLINIC JACKSONVILLE
|
FL
|
$183,322
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R21CA227259-01
|
|
Role of human endogenous retroviruses in tumor immunity of ovarian carcinoma
|
CHIAPPINELLI, KATHERINE
|
GEORGE WASHINGTON UNIVERSITY
|
DC
|
$191,044
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R21CA218973-01A1
|
|
Validation of a genomic signature that predicts for sub-optimal debulking of epithelial ovarian cancer
|
BIRRER, MICHAEL
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$203,042
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA155025-08
|
|
The role of a BRCA1 associated complex in DNA damage response and tumor suppression
|
WANG, BIN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$380,000
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA102310-15
|
|
Role of FAK in Tumorigenesis
|
SCHLAEPFER, DAVID
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
CA
|
$331,313
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA131582-09
|
|
Identification of Ovarian Cancer Plasma Biomarkers
|
SPEICHER, DAVID
|
WISTAR INSTITUTE
|
PA
|
$452,569
|
|
Ovarian Cancer
|
2018
|
NCI
|
5K12CA090628-18
|
|
Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic
|
JATOI, AMINAH
|
MAYO CLINIC ROCHESTER
|
MN
|
$746,756
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA188571-04
|
|
DYRK1A signaling in control of cell growth, proliferation and DNA damage repair
|
LITOVCHICK, LARISA
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$341,494
|
|
Ovarian Cancer
|
2018
|
NCI
|
5K12CA076930-18
|
|
Career Development in Pediatric and Medical Oncology
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$672,442
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA193136-04
|
|
MDSCs in Ovarian Cancer
|
ZOU, WEIPING
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$498,257
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA197359-04
|
|
Stem Cell/Nanoparticle Constructs for Targeted Ovarian Cancer Therapy
|
BERLIN, JACOB
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$388,875
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA207034-03
|
|
Mechanism of evasion by ovarian cancers from anti-VEGF therapy
|
NAORA, HONAMI
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$366,000
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA196200-04
|
|
Ovarian Cancer Chemoprevention
|
BENBROOK, DORIS
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$465,809
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA184717-05
|
|
The Regulation of Cisplatin resistance in ovarian cancer
|
ZHU, WENGE
|
GEORGE WASHINGTON UNIVERSITY
|
DC
|
$328,888
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA188251-05
|
|
Molecular Insights into the Fanconi Anemia Tumor Suppressor Signaling Pathway
|
FEI, PEIWEN
|
UNIVERSITY OF HAWAII AT MANOA
|
HI
|
$319,550
|
|
Ovarian Cancer
|
2018
|
NCI
|
2R01CA124515-13
|
|
Regulatory Dendritic Cells in Cancer
|
CONEJO-GARCIA, JOSE
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$367,650
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA199004-04
|
|
Targeting the vascularity for delivery of inhibitors of metastasis in ovarian cancer
|
MOR, GIL
|
YALE UNIVERSITY
|
CT
|
$511,177
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R01CA219495-01A1
|
|
Inhibin function in tumor angiogenesis
|
KARTHIKEYAN, MYTHREYE
|
UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
|
SC
|
$16,102
|
|
Ovarian Cancer
|
2018
|
NIGMS
|
1R01CA219495-01A1
|
|
Inhibin function in tumor angiogenesis
|
KARTHIKEYAN, MYTHREYE
|
UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
|
SC
|
$320,000
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R01CA219829-01A1
|
|
Exosomes and platinum-induced peripheral neuropathy
|
ZHANG, ZHENG GANG
|
HENRY FORD HEALTH SYSTEM
|
MI
|
$358,545
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA196988-02
|
|
Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancer
|
ANTALIS, TONI
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$353,419
|
|
Ovarian Cancer
|
2018
|
NIBIB
|
5R01EB020605-03
|
|
Advanced Salpingoscope for Minimally-Invasive Imaging of the Fallopian Tubes
|
BARTON, JENNIFER
|
UNIVERSITY OF ARIZONA
|
AZ
|
$299,559
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R01CA217931-01A1
|
|
Pre-metastatic Omental Niche Formation in Ovarian Cancer
|
NAORA, HONAMI
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$383,129
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA163377-07
|
|
Targeting EZH2 in CARM1-expressing epithelial ovarian cancer
|
ZHANG, RUGANG
|
WISTAR INSTITUTE
|
PA
|
$406,125
|
|
Ovarian Cancer
|
2018
|
NCI
|
5F30CA203095-03
|
|
Transcriptomic profiling and functional characterization of fusion genes in recurrent ovarian cancer
|
PRIEDIGKEIT, NOLAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$49,524
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P30CA006973-55
|
8090
|
Breast and Ovarian Cancer Program - 08
|
STEARNS, VERED
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$36,914
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R01CA216436-01A1
|
|
Nanoscale Coordination Polymers Co-deliver Chemotherapeutics and siRNAs for Efficacious Treatment of Resistant Ovarian Cancer
|
LIN, WENBIN
|
UNIVERSITY OF CHICAGO
|
IL
|
$439,699
|
|
Ovarian Cancer
|
2018
|
NHLBI
|
5R34HL135226-02
|
|
Thromboprophylaxis with rosuvastatin following surgery for ovarian cancer
|
ZWICKER, JEFFREY
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$220,500
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA135354-08
|
|
ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$380,000
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA213119-02
|
|
Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer
|
KASAHARA, NORIYUKI
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$504,040
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R01CA219187-01A1
|
|
Hedgehog/Gli1-targeted therapies to overcome ovarian cancer chemoresistance and disease recurrence
|
PALLE, KOMARAIAH
|
UNIVERSITY OF SOUTH ALABAMA
|
AL
|
$350,750
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA211975-02
|
|
Cell Cycle Blockade and Therapeutic Sensitization
|
SIDDIK, ZAHID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$366,000
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA208753-03
|
|
Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid Malignancies
|
ORSULIC, SANDRA
|
CEDARS-SINAI MEDICAL CENTER
|
CA
|
$400,313
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA159981-06
|
|
RPCI-UPCI Ovarian Cancer SPORE
|
ODUNSI, KUNLE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$1,750,206
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R21CA215662-01A1
|
|
The effects of moderate exercise on distress, quality of life, and biomarkers of angiogenesis and chronic stress in ovarian cancer survivors
|
PENNINGTON, KATHRYN
|
UNIVERSITY OF WASHINGTON
|
WA
|
$236,632
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA160331-07
|
|
Chromatin basis of cellular senescence and its implication in epithelial ovarian cancer
|
ZHANG, RUGANG
|
WISTAR INSTITUTE
|
PA
|
$423,225
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA187209-05
|
|
Functional analysis of BRCA1 in DNA damage response and tumor suppression
|
YU, XIAOCHUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$352,750
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA207497-03
|
|
Provectors for treatment of ovarian cancer
|
SUH, JUNGHAE
|
RICE UNIVERSITY
|
TX
|
$352,623
|
|
Ovarian Cancer
|
2018
|
NCI
|
5K01CA218305-02
|
|
The Impact of Maternal Obesity on the Reprogramming of the Metastatic Microenvironment
|
HILLIARD, TYVETTE
|
UNIVERSITY OF NOTRE DAME
|
IN
|
$103,375
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R50CA211280-03
|
|
Discovery and Characterization of Mutations in Breast and Ovarian Cancers
|
ADAMSON, AARON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$215,047
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R35CA197458-04
|
|
GENOMIC ANALYSIS OF INHERITED BREAST AND OVARIAN CANCER
|
KING, MARY-CLAIRE
|
UNIVERSITY OF WASHINGTON
|
WA
|
$899,750
|
|
Ovarian Cancer
|
2018
|
NIGMS
|
5R01GM059078-19
|
|
Molecular Probes for Biomembrane Recognition
|
SMITH, BRADLEY
|
UNIVERSITY OF NOTRE DAME
|
IN
|
$376,927
|
|
Ovarian Cancer
|
2018
|
NINR
|
5R21NR016905-02
|
|
Testing an Intelligent Tutoring System Intervention to Enhance Genetic Risk Assessment in Underserved Blacks and Latinas at Risk of Hereditary Breast Cancer
|
HURTADO DE MENDOZA CASAUS, ALEJANDRA
|
GEORGETOWN UNIVERSITY
|
DC
|
$235,125
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA210370-03
|
|
Early detection of ovarian cancer by serum marker and targeted ultrasound imaging
|
BARUA, ANIMESH
|
RUSH UNIVERSITY MEDICAL CENTER
|
IL
|
$356,233
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P30CA036727-32
|
5725
|
Molecular and Biochemical Etiology (MBE)
|
BAND, HAMID
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$64,409
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U24CA209999-03
|
|
Monitoring tumor subclonal heterogeneity over time and space
|
MARTH, GABOR
|
UNIVERSITY OF UTAH
|
UT
|
$754,072
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R03CA212127-02
|
|
The role of X chromosome inactivation in ovarian cancer
|
WINHAM, STACEY
|
MAYO CLINIC ROCHESTER
|
MN
|
$79,500
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R25CA217723-02
|
|
Programa de ARBOLES Familiares: Assessing Risk of Breast Cancer through Outreach to Latinas with Education and Support
|
GRAVES, KRISTI
|
GEORGETOWN UNIVERSITY
|
DC
|
$324,001
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA181808-05
|
|
Steroid Hormones Regulate Ovarian Cancer Progression and Metastasis
|
RICHARDS, JOANNE
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$336,565
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA142746-09
|
|
Enzyme-instructed self-assembly for molecular anticancer nanomedicines
|
XU, BING
|
BRANDEIS UNIVERSITY
|
MA
|
$368,145
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA136393-09
|
7019
|
Biospecimens and Patient Registry
|
KEENEY, GARY
|
MAYO CLINIC ROCHESTER
|
MN
|
$129,460
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA136393-09
|
7020
|
Core C - Biostatistics Core
|
OBERG, ANN
|
MAYO CLINIC ROCHESTER
|
MN
|
$160,946
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA136393-09
|
7021
|
Core D - Animal Models Core
|
HALUSKA, PAUL
|
MAYO CLINIC ROCHESTER
|
MN
|
$148,438
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA136393-09
|
7022
|
Administrative Core
|
KAUFMANN, SCOTT
|
MAYO CLINIC ROCHESTER
|
MN
|
$577,791
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA136393-09
|
7023
|
Project 1 - PARP Project
|
KAUFMANN, SCOTT
|
MAYO CLINIC ROCHESTER
|
MN
|
$188,026
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA136393-09
|
7024
|
Project 6 - PKC Iota
|
FIELDS, ALAN
|
MAYO CLINIC ROCHESTER
|
MN
|
$285,250
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA136393-09
|
7025
|
Project 7 - Metformin
|
LENGYEL, ERNST
|
MAYO CLINIC ROCHESTER
|
MN
|
$354,079
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA136393-09
|
7026
|
Project 8 - TH17 Dendritic Cell Vaccine
|
KNUTSON, KEITH
|
MAYO CLINIC ROCHESTER
|
MN
|
$306,610
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA136393-09
|
7027
|
Developmental Reserach Pilot Projects
|
CLIBY, WILLIAM
|
MAYO CLINIC ROCHESTER
|
MN
|
$99,600
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA136393-09
|
7028
|
Career Development
|
GOODE, ELLEN
|
MAYO CLINIC ROCHESTER
|
MN
|
$49,800
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA188025-05
|
|
Iron addiction and the biology of ovarian cancer
|
TORTI, SUZY
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
CT
|
$334,287
|
|
Ovarian Cancer
|
2018
|
NCI
|
1F30CA221004-01A1
|
|
Mechanisms of B-Myb oncogenicity in ovarian cancer
|
INESS, AUDRA
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$34,856
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U54CA163066-08
|
6613
|
Roles of proinflammatory chemokines linking obesity and ovarian cancer
|
WHALEN, MARGARET
|
TENNESSEE STATE UNIVERSITY
|
TN
|
$17,302
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R43CA221464-01A1
|
|
Novel peptide drug conjugates for the treatment of triple-negative breast cancers: Direct anti-tumor activity and immuno-oncology preclinical studies.
|
LAMHARZI, NAJIB
|
ONCOTHERAPY SOLUTIONS, LLC
|
WA
|
$300,000
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA157664-09
|
|
Initiation and Evolution of the Ovarian Cancer Microenvironment
|
CONEJO-GARCIA, JOSE
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$408,500
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P30CA047904-30
|
6388
|
Cancer Epidemiology and Prevention Program (Project-005)
|
YUAN, JIAN-MIN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$35,797
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P30CA047904-30
|
6390
|
Breast and Ovarian Cancer Program (Project-007)
|
LEE, ADRIAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$34,500
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA116201-13
|
8257
|
01 Project 1: Cancer risks for mutations in breast cancer predisposition genes
|
COUCH, FERGUS
|
MAYO CLINIC ROCHESTER
|
MN
|
$508,510
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R03CA208494-02
|
|
Development of Cell-based Functional Tests for Rare Germline ATM Gene Variants in Hereditary Ovarian Cancer Families
|
TAINSKY, MICHAEL
|
WAYNE STATE UNIVERSITY
|
MI
|
$77,000
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U24CA210954-03
|
|
iPGDAC, An Integrative Proteogenomic Data Analysis Center for CPTAC
|
ZHANG, BING
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$973,045
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P01CA190174-04
|
7470
|
Adminstrative Core
|
SPRIGGS, DAVID
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$104,237
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P01CA190174-04
|
7471
|
Biostatistics Core
|
IASONOS, ALEXIA
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$81,105
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P01CA190174-04
|
7472
|
Pathology Core
|
DELAIR, DEBORAH
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$104,236
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P01CA190174-04
|
7473
|
MUC16 Antibody Based Strategies for Imaging and Therapy
|
SPRIGGS, DAVID
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$729,636
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P01CA190174-04
|
7474
|
Personalized Immunotherapy of Patients with Ovarian Cancer
|
SABBATINI, PAUL
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$625,397
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P01CA190174-04
|
7476
|
Enhanced Efficacy of MUC16 directed antibodies through modification of the Fc domain
|
RAVETCH, JEFFREY
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$389,221
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U01CA202144-04
|
|
Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics
|
ALTER, ORLY
|
UNIVERSITY OF UTAH
|
UT
|
$741,952
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U24CA210955-03
|
|
PNNL Proteome Characterization Center
|
LIU, TAO
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
WA
|
$1,063,923
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA207456-03
|
|
Epidemiology and biology of lncRNAs in ovarian cancer
|
SELLERS, THOMAS
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$871,042
|
|
Ovarian Cancer
|
2018
|
NCI
|
5F31CA192891-05
|
|
Evaluating Notch Signaling as a Therapeutic Target in Ovarian Cancer
|
PRICE, JESSICA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$49,524
|
|
Ovarian Cancer
|
2018
|
NIGMS
|
5SC2GM122686-02
|
|
Targeted Promoter Demethylation in Ovarian Cancer Cells
|
SUNG, CHANG
|
TEXAS A&M UNIVERSITY-KINGSVILLE
|
TX
|
$137,999
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U54CA163069-08
|
6965
|
Roles of proinflammatory chemokines linking obesity and ovarian cancer
|
SON, DEOK-SOO
|
MEHARRY MEDICAL COLLEGE
|
TN
|
$77,861
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U54CA163072-09
|
6543
|
Roles of proinflammatory chemokines linking obesity and ovarian cancer
|
BEEGHLY-FADIEL, ALICIA
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
TN
|
$18,424
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA188943-04
|
|
Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors
|
HILDEBRANDT, MICHELLE
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$1,008,680
|
|
Ovarian Cancer
|
2018
|
NCI
|
5K08CA211362-03
|
|
Defining the formation and function of carcinoma-associated mesenchymal stem cells in the ovarian cancer microenvironment
|
COFFMAN, LAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$166,050
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R21CA210210-02
|
|
Targeting Cyclin E in Ovarian Cancer with Histone Deacetylase Inhibitors
|
KHABELE, DINEO
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
KS
|
$202,078
|
|
Ovarian Cancer
|
2018
|
NIGMS
|
5R01GM088055-19
|
|
Expanding Roles of E2 and E3 Enzymes in Ubiquitin Transfer
|
KLEVIT, RACHEL
|
UNIVERSITY OF WASHINGTON
|
WA
|
$563,419
|
|
Ovarian Cancer
|
2018
|
NCI
|
5UM1CA182910-06
|
|
Shanghai Womens Health Study
|
ZHENG, WEI
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
TN
|
$1,268,648
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R43CA224579-01A1
|
|
Sprayable, Prompt Color Changing Dye to Delineate Ovarian Cancer During Surgery
|
GRAY, BRIAN
|
MOLECULAR TARGETING TECHNOLOGIES, INC.
|
PA
|
$229,603
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R43CA224450-01A1
|
|
Preclinical Evaluation of VAX014 in Combination with Immune Checkpoint Inhibitors
|
GIACALONE, MATTHEW
|
VAXIION THERAPEUTICS, INC.
|
CA
|
$232,276
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U01CA217842-02
|
|
Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer
|
MILLS, GORDON
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$739,552
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P01CA087969-19
|
8092
|
Core A: Biospecimen and High-Dimensional Data Management Core
|
TWOROGER, SHELLEY
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$629,241
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P01CA087969-19
|
8096
|
Project 3: Ovarian Cancer
|
TWOROGER, SHELLEY
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$326,903
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P01CA087969-19
|
8097
|
Project 4: Statistical Innovations
|
ROSNER, BERNARD
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$167,985
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA181663-03
|
|
Mechanisms of radioresistance and strategies for radiosensitization in OCCC
|
PENG, GUANG
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$368,805
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA214799-02
|
|
Compensatory mechanisms that promote homologous recombination in BRCA1 mutant cancers
|
JOHNSON, NEIL
|
RESEARCH INST OF FOX CHASE CAN CTR
|
PA
|
$418,613
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R44CA192569-03
|
|
Tumor-Specific Fluorescent Cocktail Enables Image-Guided Cytoreductive Surgery
|
KULARATNE, SUMITH
|
ON TARGET LABORATORIES, LLC
|
IL
|
$549,126
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA220468-02
|
|
Organic nanoparticles for dual MRI-guided therapeutic selection and ovarian cancer drug delivery
|
JOHNSON, JEREMIAH
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$509,485
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R01CA207365-02
|
|
Precision Assessment and Delivery of Cancer Risks in BRCA 1/2 Mutation Cancers
|
REBBECK, TIMOTHY
|
DANA-FARBER CANCER INST
|
MA
|
$642,340
|
|
Ovarian Cancer
|
2018
|
NCI
|
5R03CA216127-02
|
|
A New Ovarian Cancer Mouse Model Based on Nanoparticle Gene Delivery
|
YANG, YANG
|
YALE UNIVERSITY
|
CT
|
$83,750
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U54CA163071-07
|
5955
|
Adrenergic modulation of ovarian cancer progression and chemoresistance
|
ARMAIZ-PENA, GUILLERMO
|
PONCE SCHOOL OF MEDICINE
|
PR
|
$77,733
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA217685-02
|
5104
|
Administrative Core
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$165,684
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA217685-02
|
5105
|
Core 1: Pathology Core
|
BROADDUS, RUSSELL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$231,014
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA217685-02
|
5106
|
Core 2: Bioinformatics and Biostatistics Core
|
BAGGERLY, KEITH
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$176,085
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA217685-02
|
5107
|
Project 1: High Grade Cancers: Capitalizing on PARPness in Ovarian Carcinoma
|
MILLS, GORDON
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$370,022
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA217685-02
|
5109
|
Project 3: The Role of Macrophages in Resistance to Anti-VEGF Drugs in Ovarian Cancer
|
COLEMAN, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$370,464
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA217685-02
|
5110
|
Project 4: SIK2 PROVIDES A NOVEL TARGET FOR OVARIAN CANCER THERAPY IN COMBINATION WITH PACLITAXEL AND INHIBITORS OF PARP
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$340,355
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA217685-02
|
5111
|
Developmental Research Program
|
SOOD, ANIL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$80,000
|
|
Ovarian Cancer
|
2018
|
NCI
|
5P50CA217685-02
|
5112
|
Career Enhancement Program
|
SOOD, ANIL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$80,000
|
|
Ovarian Cancer
|
2018
|
NCI
|
1P50CA228991-01
|
8871
|
Admin Core
|
SHIH, IE-MING
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$189,072
|
|
Ovarian Cancer
|
2018
|
NCI
|
1P50CA228991-01
|
8872
|
Biorepository/Pathology Core
|
FADER, AMANDA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$314,958
|
|
Ovarian Cancer
|
2018
|
NCI
|
1P50CA228991-01
|
8873
|
Biostatistics Core
|
HUANG, PENG
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$159,210
|
|
Ovarian Cancer
|
2018
|
NCI
|
1P50CA228991-01
|
8874
|
"Applying PapGene test for early ovarian cancer detection"
|
PAPADOPOULOS, NICKOLAS
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$501,816
|
|
Ovarian Cancer
|
2018
|
NCI
|
1P50CA228991-01
|
8875
|
"Optimizing synthetic lethality in high-grade serous ovarian cancer"
|
SIMPKINS, FIONA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$374,652
|
|
Ovarian Cancer
|
2018
|
NCI
|
1P50CA228991-01
|
8876
|
Overcoming platinum resistance in ovarian cancer through BET inhibition.
|
ZHANG, RUGANG
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$367,780
|
|
Ovarian Cancer
|
2018
|
NCI
|
1P50CA228991-01
|
8877
|
"Exploring the potential of SYK inhibitors to sensitize ovarian cancer to the anti-tumor effects of paclitaxel"
|
SHIH, IE-MING
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$345,550
|
|
Ovarian Cancer
|
2018
|
NCI
|
1P50CA228991-01
|
8878
|
Developmental Research Program
|
DRAPKIN, RONNY
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$111,875
|
|
Ovarian Cancer
|
2018
|
NCI
|
1P50CA228991-01
|
8879
|
Career Enhancement Program
|
BURGER, ROBERT
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$127,624
|
|
Ovarian Cancer
|
2018
|
NIMHD
|
5U54MD007600-32
|
5317
|
Upstream Regulation and Downstream effectors of c-MYC in Ovarian Cancer
|
VIVAS-MEJIA, PABLO
|
UNIVERSITY OF PUERTO RICO MED SCIENCES
|
PR
|
$340,378
|
|
Ovarian Cancer
|
2018
|
NCI
|
5U54CA163068-07
|
5836
|
Adrenergic modulation of ovarian cancer progression and chemoresistance
|
MONTEIRO, ALVARO
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$84,062
|
|
Ovarian Cancer
|
2018
|
NCI
|
1R21CA229044-01
|
|
Novel platform linking cancer-specific glycosylation with cell signaling outcomes
|
ABBOTT, KAREN
|
UNIV OF ARKANSAS FOR MED SCIS
|
AR
|
$225,250
|
|
Ovarian Cancer
|
2018
|
NHLBI
|
3R01HL132251-02S1
|
|
The Roles and Regulation of BRCA1 in Hematopoiesis
|
ROSS, THEODORA
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$124,170
|
|
